Screener / Biotech / Intellia Therapeutics
NTLA · NASDAQ
Intellia Therapeutics
Compliant
Under AAOIFI Standard 21, Intellia Therapeutics is compliant. Its core business is permissible and its interest-bearing debt is below 30% of market cap.
TickerNTLA
ExchangeNASDAQ
SectorBiotech
Full ratios for Intellia Therapeutics (impure revenue, debt and interest-bearing deposits under all four standards) are being added. Until then this page shows the screening verdict only. See the methodology for how each test works. Purindex publishes this screening to help people understand what they own. It does not recommend buying, selling or holding Intellia Therapeutics or any other security.